article thumbnail

Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP generics

Fierce Pharma

Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP generics aliu Thu, 03/30/2023 - 16:18

Pharma 229
article thumbnail

The Sales Pro’s Guide to Sales Prospecting

Integrity Solutions

Sales prospecting is vital to the success of any sales organization. Why Is Sales Prospecting More Important Than Ever? They’ve also put new pressure on salespeople to hone their prospecting skills and redouble their efforts so they can turn effective sales prospecting into their success differentiator.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

B2B Sales Prospecting: What You Need To Know

Spotio

Business-to-business (B2B) prospecting is the pillar of lead generation. When prospecting for new business, the goal is to identify as many quality prospects as possible. However, B2B sales prospecting strategy is not as easy as it sounds. When it comes to prospecting, B2B companies face a quality and quantity problem.

article thumbnail

Ardelyx FDA docs portend another showdown at this week's expert hearing on kidney disease prospect

Fierce Pharma

Ardelyx FDA docs portend another showdown at this week's expert hearing on kidney disease prospect. fkansteiner. Tue, 11/15/2022 - 10:30.

FDA 272
article thumbnail

After 2 rejections, FDA panel rallies around Ardelyx's kidney disease prospect

Fierce Pharma

After 2 rejections, FDA panel rallies around Ardelyx's kidney disease prospect. fkansteiner. Thu, 11/17/2022 - 06:51.

FDA 157
article thumbnail

GSK's daprodustat will have to face FDA expert panel first as oral CKD anemia prospect targets nod that stumped AstraZeneca, Otuska rivals

Fierce Pharma

GSK's daprodustat will have to face FDA expert panel first as oral CKD anemia prospect targets nod that stumped AstraZeneca, Otuska rivals. fkansteiner. Tue, 09/06/2022 - 16:05.

FDA 242
article thumbnail

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO

Fierce Pharma

Despite CMS snub, Eisai is 'not so nervous' about Leqembi's long-term coverage prospects: US CEO fkansteiner Tue, 03/21/2023 - 09:41